Scienture wins third US patent for ARBLI oral suspension, protection through 2041

Scienture Holdings, Inc.

Scienture Holdings, Inc.

SCNX

0.00
  • Scienture won a third US patent covering ARBLI, a ready-to-use oral suspension of losartan potassium.
  • USPTO issued US Patent No. 12,605,365 on April 21, 2026; protection expected to run through Oct. 7, 2041.
  • ARBLI is positioned for US losartan market estimated at $241 million in annual sales with about 72 million prescriptions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scienture Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605060805PRIMZONEFULLFEED9714218) on May 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.